IRVINE, Calif., Sept. 4, 2026, 2:15 p.m. PDT — Tarsus Pharmaceuticals NASDAQ:TARS shares jumped 9.1% Friday after the company completed its Alkeus acquisition. At the $90.78 close, the stock consideration carried a market value of about $266.2 million. That puts the upfront package near $536.2 million at current prices.
The contract still calls for $270 million in cash and shares valued at $180 million when the deal was signed. Tarsus priced those shares at $61.38 each. Friday’s close exposes the higher economic value of equity already promised to Alkeus holders.
- Tarsus closed at $90.78, up $7.58, after trading between $81.07 and $91.53.
- The 2.93 million acquisition shares are now worth about $266.2 million.
- Those shares represent roughly 6.0% of estimated pro forma share equivalents.
- The pivotal NORTHSTAR study is expected to report topline results in the second half of 2029.
The shares finished near their session high on volume of 1.60 million. They gained $7.58 from Thursday’s $83.21 close. The move added an estimated $371.5 million to pro forma equity value.
Tarsus climbed for a third straight session
Daily closing price, Aug. 31 through Sept. 4, 2026
Price data: Yahoo Finance. Close recorded at . Prices are unadjusted in this five-session view.
A rising share price makes the consideration dearer
Alkeus holders receive about 2.93 million Tarsus shares, based on the disclosed reference price. Their value has risen roughly $86.2 million above the original $180 million figure. The legal payment did not change.
The $450 million headline has a $536 million current value
TS2 calculation using disclosed consideration and Friday’s closing price
Terms: Tarsus quarterly filing. Current-value estimate uses Friday’s close and excludes royalties. The $250 million regulatory milestone may be paid in cash, stock or both at Tarsus’s option.
That distinction cuts both ways. Alkeus sellers participate in Tarsus’s rally, while existing owners absorb the extra shares. The deal shares equal about 6.0% of an estimated 49.0 million pro forma share equivalents.
Tarsus also raised $125 million in a private placement tied to the transaction. Its June balance sheet held $449.7 million in cash and marketable securities. A rough bridge leaves $267.2 million after two acquisition cash payments and the financing.
That estimate comes before fees and operating cash use. It also treats pre-funded warrants as share equivalents. Post-quarter option exercises or vesting could shift the final count.
XDEMVY is financing the wait
Tarsus enters the deal with a growing commercial product. Second-quarter XDEMVY sales rose 69% to $173.9 million. Management guided to $685 million through $705 million for the full year.
Spending is rising alongside sales. Research and development expense nearly doubled to $31.0 million during the quarter. Selling, general and administrative expense reached $150.7 million, up from $103.0 million.
Commercial cash now supports a three-year clinical wait
Current resources, dilution and the pivotal program’s next defining event
Sources: Tarsus completion release, its quarterly filing, and the acquisition presentation. Liquidity and share counts are preliminary TS2 estimates before ongoing operations, fees and later equity activity.
The clinical answer remains three years away
Gildeuretinol targets Stargardt disease, an inherited retinal disorder with no FDA-approved therapy. Tarsus estimates 86,000 US patients, including about 36,000 with a diagnosis. The addressable group is meaningful for an orphan medicine.
Earlier studies provide a signal rather than pivotal proof. In the company-reported TEASE-1 study, lesion growth slowed 29.5% against an untreated arm. TEASE-2 found a lower risk of significant low-light vision loss.
NORTHSTAR plans to enroll roughly 230 patients. Its primary endpoint measures retinal lesion growth over 24 months. Low-light visual acuity supplies a key secondary measure.
Chief Executive Bobby Azamian said the company’s focus is “advancing the NORTHSTAR trial.” Topline results are due in the second half of 2029. That timetable leaves execution, enrollment and cash use visible for many quarters.
The stock’s 48% rise since Aug. 5 cannot be assigned solely to Alkeus. Tarsus also reported XDEMVY growth and raised capital during that span. Friday’s timing suggests investors assigned fresh value when ownership became final.
Risks
The largest risk sits inside the 2029 readout. Earlier trials were small, and their findings may not repeat in NORTHSTAR. A delay would extend spending before any possible product revenue.
Dilution remains a second variable. Regulatory milestones can be settled partly in Tarsus shares, while commercial success could add $100 million in cash payments. Royalties would follow any approved sales.
Investors now have a clean measuring stick. XDEMVY must support the enlarged pipeline without eroding liquidity too quickly. NORTHSTAR must then justify an upfront package whose current value already exceeds half a billion dollars.
